| 任文娟,李佳,高春燕,等.阿糖腺苷对 EB病毒相关性传染性单核细胞增多症 T细胞亚群的影响[J].安徽医药,2020,24(11):2291-2294. |
| 阿糖腺苷对 EB病毒相关性传染性单核细胞增多症 T细胞亚群的影响 |
| Effects of vidarabine on T lymphocyte subsets in children with EBV associated infectious mononucleosis |
| |
| DOI：10.3969/j.issn.1009?6469.2020.11.045 |
| 中文关键词: 传染性单核细胞增多症 阿糖腺苷 EB病毒 T细胞亚群 |
| 英文关键词: Infectious mononucleosis Vidarabine EBV virus T lymphocyte subsets |
| 基金项目: |
|
| 摘要点击次数: 1539 |
| 全文下载次数: 411 |
| 中文摘要: |
| 目的研究阿糖腺苷对 EB病毒(EBV)相关性传染性单核细胞增多症(EBV?IM)病儿 T细胞亚群的影响。方法选取 2015年 3月至 2018年 6月入住延安大学附属医院的 EBV?IM病儿 96例，依据随机数字表法分为阿糖腺苷组(n＝48)及对照组(n＝48)阿糖腺苷组给予常规治疗 +阿糖腺苷治疗，对照组给予常规治疗 +更昔洛韦治疗。观察两组临床症状恢复时间、住院时间，治疗，后 7、10 d EBV?DNA、EA?IgG及 VCA?IgM阴转情况，治疗前后 T细胞亚群水平，临床疗效及不良反应。结果阿糖腺苷组临床症状恢复时间及住院时间［(18.18±0.99)d比(21.57±2.31)d］均小于对照组(P＜0.05)。治疗后 7d、10 d，阿糖腺苷组 EBV?DNA、EA?IgG及 VCA?IgM阴转率均高于对照组(P＜0.05)。治疗后，阿糖腺苷组 CD3+、CD3+CD4+、CD4-/CD8-水平均低于对照组， CD3+CD8+、CD4+/CD8+均高于对照组(P＜0.05)。阿糖腺苷组总有效率(95.83%)高于对照组(75.00%)(P＜0.05)。治疗期内，阿糖腺苷组不良反应发生率(4.17%)低于对照组(20.83%)(P＜0.05)。结论阿糖腺苷应用于 EBV?IM病儿的临床治疗，可有效杀灭 EBV，纠正免疫紊乱，改善 T细胞亚群，提高机体免疫功能，疗效显著，安全性高，值得应用于临床。 |
| 英文摘要: |
| Objective To study effects of vidarabine on T lymphocyte subsets in children with EBV virus?associated infectious mononucleosis(EBV?IM).Methods A total of 96 children with EBV?IM admitted to Affiliated Hospital of Yan’an University from March 2015 to June 2018 were included in this study.According to the random number table method，they were divided into two groups:vidarabine group(n＝48)and control group(n＝48)，and the vidarabine group was given routine treatment + vidarabi? ne treatment，the control group was given routine treatment + ganciclovir treatment.The recovery time of clinical symptoms，hospital? ization time，EBV?DNA，EA?IgG and VCA?IgM negative conversion on the 7，10 d after treatment，T cell subgroup level before and after treatment，clinical efficacy and adverse reactions in the two groups were observed.Results T，he clinical symptom recovery time and hospitalization time of the vidarabine group［(18.18±0.99)d vs.(21.57±2.31)d］were shorter than that of the control group(P＜0.05).Seven and ten days after treatment，the negative conversion rates of EBV?DNA，EA?IgG and VCA?IgM of the vida? rabine group were higher than those in the control group(P＜0.05).After treatment，the levels of CD3+，CD3+CD4+ and CD4-/ CD8-in the vidarabine group were lower than those in the control group，CD3+CD8+ and CD4+/CD8+ were higher than the control group(P＜0.05).The total efficiency of the vidarabine group(95.83%)was higher than that of the control group(75.00%)(P＜0.05).The incidence of adverse reactions in the vidarabine group(4.17%)was lower than that in the control group(20.83%)(P＜0.05)during the treatment period.Conclusion Vidarabine used in clinical treatment of children with EBV?IM can effectively kill EBV，correct immune disorder，improve T cell subsets，improve the immune function of the body，with remarkable curative effect and good safety，which is worthy of clinical application. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
